小细胞肺癌的分子分型及其治疗策略的研究进展

Small cell lung cancer (SCLC) is a malignant tumor with remarkable proliferative and invasive ability, which has very poor clinical prognosis due to lack of effective treatments. In recent years, researches on cells, animal models and tumor samples have promoted the identification of molecular subtypes of SCLC, discovered unique biological and clinical characteristics, and proposed potential specific therapeutic targets for different subtypes. This will encourage the development of more accurate therapeutic strategies towards SCLC, with a view to improving the prognosis of the patients. This article will review the current SCLC molecular subtypes, focus on the clinical characteristics and therapeutic strategies of different SCLC subtypes, and propose reasonable suggestions for the future treatment of SCLC.
.

[1]  Lei-na Sun,et al.  Abemaciclib抑制c-Myc高表达小细胞肺癌增殖、侵袭和迁移的生物学功能的研究 , 2023, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

[2]  F. Tang,et al.  Single-cell transcriptomic profiling reveals the tumor heterogeneity of small-cell lung cancer , 2022, Signal Transduction and Targeted Therapy.

[3]  Zibo Zhao,et al.  POU2AF2/C11orf53 functions as a coactivator of POU2F3 by maintaining chromatin accessibility and enhancer activity , 2022, bioRxiv.

[4]  R. Ricci,et al.  Promoters of ASCL1‐ and NEUROD1‐dependent genes are specific targets of lurbinectedin in SCLC cells , 2022, EMBO molecular medicine.

[5]  Lujun Zhao,et al.  Prognostic Implications of Molecular Subtypes in Primary Small Cell Lung Cancer and Their Correlation With Cancer Immunity , 2022, Frontiers in Oncology.

[6]  K. Sutherland,et al.  Killing SCLC: insights into how to target a shapeshifting tumor , 2022, Genes & development.

[7]  J. Ying,et al.  ASCL1 and DLL3 expressions and their clinicopathological implications in surgically resected pure small cell lung cancer: A study of 247 cases from the National Cancer Center of China , 2021, Thoracic cancer.

[8]  Vianne R. Gao,et al.  Signatures of plasticity, metastasis, and immunosuppression in an atlas of human small cell lung cancer. , 2021, Cancer cell.

[9]  Pinglong Xu,et al.  YAP drives fate conversion and chemoresistance of small cell lung cancer , 2021, Science advances.

[10]  Y. Liu,et al.  Anlotinib vs placebo as third- or further-line treatment for patients with small cell lung cancer: a randomised, double-blind, placebo-controlled Phase 2 study , 2021, British Journal of Cancer.

[11]  W. Klepetko,et al.  Molecular profiles of small cell lung cancer subtypes: therapeutic implications , 2021, Molecular therapy oncolytics.

[12]  P. Robson,et al.  Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities. , 2021, Cancer cell.

[13]  L. Byers,et al.  The role of Schlafen 11 (SLFN11) as a predictive biomarker for targeting the DNA damage response , 2020, British Journal of Cancer.

[14]  M. Millward,et al.  Tumour PD-L1 Expression in Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis , 2020, Cells.

[15]  L. Girard,et al.  A biobank of small cell lung cancer CDX models elucidates inter- and intratumoral phenotypic heterogeneity , 2020, Nature Cancer.

[16]  Bora Lim,et al.  Advancing Cancer Research and Medicine with Single-Cell Genomics. , 2020, Cancer cell.

[17]  L. Soucek,et al.  MYC, MYCL, and MYCN as therapeutic targets in lung cancer , 2020, Expert opinion on therapeutic targets.

[18]  C. Rudin,et al.  Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY Study , 2019, Clinical Cancer Research.

[19]  Nicholas T. Ingolia,et al.  MYC-Driven Small-Cell Lung Cancer is Metabolically Distinct and Vulnerable to Arginine Depletion , 2019, Clinical Cancer Research.

[20]  C. Rudin,et al.  Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data , 2019, Nature Reviews Cancer.

[21]  C. Rudin,et al.  Targeting NOTCH activation in small cell lung cancer through LSD1 inhibition , 2019, Science Signaling.

[22]  Leng Han,et al.  Comprehensive Molecular Characterization of the Hippo Signaling Pathway in Cancer , 2018, Cell reports.

[23]  H. Bolouri,et al.  Crebbp Loss Drives Small Cell Lung Cancer and Increases Sensitivity to HDAC Inhibition. , 2018, Cancer discovery.

[24]  C. Rudin,et al.  Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  Steven J. M. Jones,et al.  Oncogenic Signaling Pathways in The Cancer Genome Atlas. , 2018, Cell.

[26]  Tatsuya Yamaguchi,et al.  Skn-1a/Pou2f3 functions as a master regulator to generate Trpm5-expressing chemosensory cells in mice , 2017, PloS one.

[27]  J. Minna,et al.  Small-cell lung cancer: what we know, what we need to know and the path forward , 2017, Nature Reviews Cancer.

[28]  R. Satija,et al.  Single-cell RNA sequencing to explore immune cell heterogeneity , 2017, Nature Reviews Immunology.

[29]  L. Lam,et al.  Vulnerability of Small-Cell Lung Cancer to Apoptosis Induced by the Combination of BET Bromodomain Proteins and BCL2 Inhibitors , 2017, Molecular Cancer Therapeutics.

[30]  Kristofer C. Berrett,et al.  MYC Drives Progression of Small Cell Lung Cancer to a Variant Neuroendocrine Subtype with Vulnerability to Aurora Kinase Inhibition. , 2017, Cancer cell.

[31]  J. Nieva,et al.  A Randomized Phase II Study of Linsitinib (OSI-906) Versus Topotecan in Patients With Relapsed Small-Cell Lung Cancer , 2016, The oncologist.

[32]  Hiroshi I. Suzuki,et al.  YAP and TAZ modulate cell phenotype in a subset of small cell lung cancer , 2016, Cancer science.

[33]  R. Huber,et al.  SCLC-State of the Art and What Does the Future Have in Store? , 2016, Clinical lung cancer.

[34]  Luc Girard,et al.  ASCL1 and NEUROD1 Reveal Heterogeneity in Pulmonary Neuroendocrine Tumors and Regulate Distinct Genetic Programs. , 2016, Cell reports.

[35]  Tao Wang,et al.  ASCL1 is a lineage oncogene providing therapeutic targets for high-grade neuroendocrine lung cancers , 2014, Proceedings of the National Academy of Sciences.

[36]  K. Guan,et al.  The Hippo signaling pathway in stem cell biology and cancer , 2014, EMBO reports.

[37]  C. Rudin,et al.  Selective tropism of Seneca Valley virus for variant subtype small cell lung cancer. , 2013, Journal of the National Cancer Institute.

[38]  J. Minna,et al.  NeuroD1 regulates survival and migration of neuroendocrine lung carcinomas via signaling molecules TrkB and NCAM , 2013, Proceedings of the National Academy of Sciences.

[39]  E. Wong,et al.  Tyrosine kinase B receptor and BDNF expression in ovarian cancers - Effect on cell migration, angiogenesis and clinical outcome. , 2009, Cancer letters.

[40]  M. Brock,et al.  Achaete-scute complex homologue 1 regulates tumor-initiating capacity in human small cell lung cancer. , 2009, Cancer research.

[41]  T. Miyata,et al.  NeuroD is required for differentiation of the granule cells in the cerebellum and hippocampus. , 1999, Genes & development.

[42]  S. Baylin,et al.  An achaete-scute homologue essential for neuroendocrine differentiation in the lung , 1997, Nature.

[43]  M. Tsai,et al.  Tissue-specific regulation of the insulin gene by a novel basic helix-loop-helix transcription factor. , 1995, Genes & development.

[44]  G. Edelman,et al.  Differential contributions of Ng-CAM and N-CAM to cell adhesion in different neural regions , 1986, The Journal of cell biology.

[45]  J. Minna,et al.  Characterization of variant subclasses of cell lines derived from small cell lung cancer having distinctive biochemical, morphological, and growth properties. , 1985, Cancer research.

[46]  C. Rudin,et al.  SCLC Subtypes De fi ned by ASCL1, NEUROD1, POU2F3, and YAP1: A Comprehensive Immunohistochemical and Histopathologic Characterization , 2020 .

[47]  K. Nackaerts,et al.  Randomized Phase II Study of Paclitaxel plus Alisertib versus Paclitaxel plus Placebo as Second-Line Therapy for SCLC: Primary and Correlative Biomarker Analyses , 2020 .

[48]  V. Velcheti,et al.  Reciprocal expression of INSM1 and YAP1 defines subgroups in small cell lung cancer , 2017, Oncotarget.

[49]  C. Rudin,et al.  Rovalpituzumab tesirine , a DLL 3-targeted antibody-drug conjugate , in recurrent small-cell lung cancer : a fi rst-inhuman , fi rst-in-class , open-label , phase 1 study , 2016 .